Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0461929603
Thu, 10.06.2021
Xlife Sciences AG
PRESS RELEASEXlife Sciences AG (XLS DE): Breakthrough in Drug Development
First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active sub [ … ]
Fri, 14.05.2021
Xlife Sciences AG
PRESS RELEASEXlife Sciences AG (XLS): Portfolio project listed on the Stock Exchange
Vitruvia Medical AG is listed on the Munich Stock Exchange since yesterday The shares of Vitruvia Medical AG are open for trading since yesterday on the Stock exchange in Munich. Vitruvia is based in Germany and Switzerland and develops circulatory systems for hig [ … ]
Wed, 31.03.2021
Xlife Sciences AG
Xlife Sciences AG (XLS): 2020 financial results
Xlife increases net profit to 21.2 million Swiss francs
In 2020, Xlife Sciences AG (XLS) significantly increased its profit to 21.2 million Swiss francs compared to the previous year (1.03 million). The increase is based on the transaction and the capital appreciation of the portfolio companies Vela [ … ]
Fri, 08.01.2021
Xlife Sciences AG
Xlife Sciences AG: Transaction with Baliopharm AG
License Deal of 300 million euros successfully completed Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based com [ … ]
Wed, 23.12.2020
Xlife Sciences AG
Xlife Sciences AG: Exit of a project company
More than 20 million euros transaction completed
Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a pa [ … ]
Fri, 04.12.2020
Xlife Sciences AG
Capial increase of Xlife Sciences AG
Successful capital raising of six million Swiss francs
Xlife Sciences AG has successfully closed its capital increase and raised a total of 6.02 million Swiss Francs of new capital as of December 3, 2020. The placement was oversubscribed at the end of the subscription period. The management of the company sees [ … ]
Thu, 03.12.2020
Xlife Sciences AG
Xlife Sciences AG: Xlife Sciences expands its project portfolio
Two new project companies offer strong synergy potentialXlife Sciences expands its project portfolio to 23 projects by adding Panmabs GmbH and Xarma Life Science GmbH, both based in Mainz. According to the management of Xlife Sciences this creates significant synergies between variou [ … ]
Mon, 02.11.2020
Xlife Sciences AG
Xlife Sciences AG: M.M. Warburg sets price target to EUR 55.75
In their recently published report, the analysts of Deutsche Bankhaus M.M. Warburg set the price target for the shares of the Swiss management company, Xlife Sciences AG (Xetra: XLS) to EUR 55.75. The company's earnings for the financial year 2020 are expected at 10.4 million euros and [ … ]
Wed, 05.08.2020
Xlife Sciences AG
Xlife Sciences AG (XLS DE, Xetra) acquires a 50% stake in palleos healthcare GmbH, Wiesbaden, Germany. Based on an approximate valuation of the company at EUR 10.0 million, the acquisition price is EUR 4.0 million and 40,000 shares of Xlife Sciences AG. Specific milestones have been agreed upon for the final settlement date and acquisition price, s [ … ]